Xenetic Biosciences, Inc. XBIOW
Set alert
At close · Jul 16
- Open
- 16.70
- Prev close
- 22.94
- Mkt cap
- 5.62M
- Vol
- 2
- Avg vol
- 635
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.54
- High
- 17.54
- Forward P/E
- 0.00
- Beta
- 2.30
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 12.44
- 200-d avg
- 9.05
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.11
- EPS (TTM)
- 0.00
- Beta
- 2.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -182.95%
- Revenue (TTM)
- 2.44M
- Revenue growth
- -15.70%
- Free cash flow
- -2.57M
- Total cash
- 7.82M
- Total debt
- 0
- Return on equity
- -41.54%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 12.44
- 200-day average
- 9.05
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xeneticbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on XBIOW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.00% | 1 | 17 | Jun 29, 2024 |